Managing integrated continuous bioprocesses in real time: Deviations in product quality.

Area of Science:

• Biopharmaceutical Manufacturing
• Chemical Engineering
• Process Control

Background:

• The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) developed the N-mAb case study.
• Focuses on advanced manufacturing process technologies, specifically integrated continuous bioprocesses (ICB) for monoclonal antibodies (mAbs).
• Aims to support education for industry professionals and regulatory bodies.

Purpose of the Study:

• To present a summary of the N-mAb case study chapter on managing deviations from a state of control in real time.
• To highlight elements unique to ICB within an integrated control strategy.
• To provide applicable insights for both ICB and rapid-cadence batch processes.

Main Methods:

• The N-mAb case study outlines the evolution of an integrated control strategy.
• Focuses on real-time deviation management within ICB.
• Summarizes key aspects of managing process deviations.

Main Results:

• Provides a comprehensive overview of managing deviations from a state of control in real time for ICB.
• Highlights the importance of real-time deviation management in advanced biopharmaceutical manufacturing.
• Demonstrates applicability to both continuous and rapid batch manufacturing processes.

Conclusions:

• Effective real-time management of deviations is critical for integrated continuous bioprocessing (ICB).
• The N-mAb case study offers valuable learning for industry and regulators on advanced biomanufacturing.
• Strategies for deviation management in ICB are also relevant for high-speed batch operations.